Autopsy report · NCT04931420

Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels

“PI left site”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of Chicago

Sponsor type

University, hospital or other

Conditions

Metastatic Cancer; Foregut Carcinoid Tumor; Gastric Adenocarcinoma; Gallbladder Adenocarcinoma; Liver Cancer; GI Cancer

Interventions

Standard of Care Chemotherapy; Video-Assisted Thoracic Surgery (VATS); Lobectomy; Consolidative Radiation; Ablation Treatment; Resection or Excision

Participants

0

Trials that died the same way

• Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
  “PI Leaving Site” (89% match in meaning)
• Analysis of Cardiac Biomarker Racial Discrepancies
  “PI no longer with the site” (77% match in meaning)
• Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure
  “Departure of PI” (65% match in meaning)
• Brain Autoregulation Research Study
  “PI departure” (63% match in meaning)
• Characterization of Explanted Hernia Meshes From Human Subjects: A Multi-Center, Prospective Study
  “PI left institution” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.